Skip to content
PharmaManufacturingIQ

What ADC toxicity reveals about payload design

Antibody-drug conjugates (ADCs) have transformed oncology therapeutics by combining the selectivity of monoclonal antibodies with the potency of highly cytotoxic small-molecule drugs. Rongrong Li, senior principal scientist, WuXi AppTec discusses.

By Olivia Friett
What ADC toxicity reveals about payload design
Published: | 4 min read
Share to X Share to Bluesky Share to Facebook Share to LinkedIn Share by email

Antibody-drug conjugates (ADCs) have transformed oncology therapeutics by combining the selectivity of monoclonal antibodies with the potency of highly cytotoxic small-molecule drugs. Rongrong Li, senior principal scientist, WuXi AppTec discusses.

WuXi AppTec

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information